A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

Conditions

• Non-alcoholic Fatty Liver Disease

Eligibility Criteria

Sex

ALL

Age

18 Years - 75 Years

Healthy Volunteers

Not accepted

Interventions

• Efimosfermin alfa — DRUG
  Efimosfermin alfa will be administered
• Efimosfermin alfa — DRUG
  Efimosfermin alfa will be administered
• Placebo — DRUG
  Placebo will be administered

Study Details

The purpose of this study is to assess the safety and efficacy of efimosfermin alfa in the resolution of steatohepatitis and improvement of liver-related clinical outcome compared to placebo in individuals with MASH and biopsy-confirmed F2- or F3-stage fibrosis.

Key Dates

Start date

Oct 24, 2025

Status verified

Apr 2026

Primary completion

Mar 29, 2028

Completion

Dec 12, 2031

Study Design

Enrollment

1,200 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Participants receiving dose level 1 of efimosfermin alfa
• Experimental: Participants receiving dose level 2 of efimosfermin alfa
• Placebo Comparator: Participants receiving Placebo

Primary Outcome Measure

Proportion of participants experiencing improvement in fibrosis by >=1 stage and no worsening of steatohepatitis at Week 52 [ Time Frame: At Week 52 ]

Central Contacts

• US GSK Clinical Trials Call Center
  877-379-3718
  [email protected]
• EU GSK Clinical Trials Call Center
  +44 (0) 20 89904466
  [email protected]

Locations (49)

Find similar trials in Arcadia, CA

Related Studies

• AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)
  Recruiting · AdventHealth Translational Research Institute · Orlando, Florida
• Quantifying Hepatic Mitochondrial Fluxes in Humans
  PHASE4 · Recruiting · The University of Texas Health Science Center at San Antonio · San Antonio, Texas
• Diet and Meal Timing in Patients With Metabolic Dysfunction Associated Steatoic Liver Disease
  Recruiting · Weill Medical College of Cornell University · New York, New York
• Impact of Soymilk on Liver Disease Severity of Children With Non-alcoholic Fatty Liver Disease (NAFLD)
  PHASE2 · Recruiting · Marialena Mouzaki · Cincinnati, Ohio